Table 1.
Characteristics of CRC patients who were 65 years or older and treated with chemotherapy with versus without bevacizumab (Bev) use.a
| n | Total 8645 |
Bev 4502 |
No Bev 4143 |
p |
|---|---|---|---|---|
| Age at first chemotherapy (years) | ||||
| 65–69 | 29.5% | 31.3% | 27.5% | <0.0001 |
| 70–74 | 27.5% | 27.9% | 27.1% | |
| 75–79 | 22.5% | 23.2% | 21.8% | |
| 80 or above | 20.5% | 17.7% | 23.6% | |
| Sex | ||||
| Male | 52.1% | 52.5% | 51.8% | 0.53 |
| Female | 47.9% | 47.5% | 48.2% | |
| Race/ethnicity | ||||
| White | 82.4% | 83.3% | 81.5% | 0.062 |
| Black | 9.1% | 9.0% | 9.2% | |
| Hispanic/Latino | 1.7% | 1.4% | 1.9% | |
| Asian | 3.8% | 3.6% | 4.0% | |
| Other | 3.0% | 2.6% | 3.4% | |
| Marital status | ||||
| Married | 57.0% | 58.6% | 55.1% | 0.001 |
| Other | 43.0% | 41.4% | 44.9% | |
| Median household income (group-level) | ||||
| Q1 | 24.1% | 23.6% | 24.6% | 0.66 |
| Q2 | 24.3% | 24.7% | 23.9% | |
| Q3 | 25.0% | 25.1% | 25.0% | |
| Q4 | 26.2% | 26.1% | 26.3% | |
| Education | ||||
| Q1 | 25.4% | 25.0% | 25.9% | 0.20 |
| Q2 | 25.3% | 25.0% | 25.7% | |
| Q3 | 24.0% | 23.8% | 24.3% | |
| Q4 | 24.9% | 25.8% | 23.8% | |
| CRC stage at diagnosis | ||||
| I | 3.1% | 2.8% | 3.4% | <0.0001 |
| II | 10.3% | 9.2% | 11.4% | |
| III | 25.8% | 21.2% | 30.7% | |
| IV | 60.9% | 66.8% | 54.5% | |
| Co-morbid conditions | ||||
| GI perforation | 2.5% | 2.2% | 2.8% | 0.062 |
| Arterial thromboembolism | 4.6% | 3.9% | 5.3% | 0.001 |
| CM/CHF | 10.2% | 8.6% | 12.0% | <0.0001 |
| Arrhythmic disorder | 17.2% | 15.2% | 19.3% | <0.0001 |
| Other cardiac condition | 66.7% | 64.3% | 69.4% | <0.0001 |
| Modified Charlson index (mean±SD) | 0.626 ±0.916 | 0.582 ±0.876 | 0.675 ±0.956 | <0.0001 |
Q1–Q4: quartile 1–quartile 4 from lowest to highest; CRC: colorectal cancer; CM/CHF: cardiomyopathy or congestive heart failure; GI: gastrointestinal; SD: standard deviation.
a
Modified Charlson index was calculated excluding all other listed conditions.